OBJECTIVES: In the UK, PCa is the most common male cancer resulting in over 10,000 deaths annually. LHRH agonists (LHRHa), a type of androgen deprivation therapy, are used to help control PCa and delay progression. LHRHa injections are available as 1-, 3- and 6-monthly formulations. Triptorelin is the only LHRHa in the UK available as a 6-monthly formulation. DESERVE aimed to collect RWE about clinical and practical outcomes for patients starting on, or switching to, 6-monthly triptorelin. METHODS: A customised data collection programme was designed including up to 2 years of data entered retrospectively by physicians from patient records at three UK hospitals and prospectively updated over a 5-month period. All patients on 6-monthly triptorelin were eligible for entry. The primary outcome measure was change in the number of patient–NHS interactions (patient reviews, PSA tests and LHRHa injections). RESULTS: CONCLUSIONS: Patient–NHS interactions were significantly reduced and PSA control was maintained with 6-monthly triptorelin vs any 3-monthly LHRHa, which translates into NHS savings and improvement in the overall patient experience. Use of 6-monthly triptorelin may therefore offer advantages over 3-monthly formulations for patients, prescribers and payors.